HOOKIPA Pharma Inc. (HOOK)

$1.4

+0.03 (+2.19%)
Rating:
Recommendation:
-
Symbol HOOK
Price $1.4
Beta 0.842
Volume Avg. 3.63M
Market Cap 76.569M
Shares () -
52 Week Range 1.25-20.0
1y Target Est -
DCF Unlevered HOOK DCF ->
DCF Levered HOOK LDCF ->
ROE -64.80% Strong Sell
ROA -39.03% Strong Sell
Operating Margin -
Debt / Equity 32.30% Neutral
P/E -
P/B 0.31 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest HOOK news


Mr. Joern Aldag
Healthcare
Biotechnology
NASDAQ Global Select

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.